Is Simplify High Yield ETF (CDX) a Buy, Sell, or Hold?
AMEX : CDX
Simplify High Yield ETF
$20.805 USD
-$0.04 (-0.22%)
- Volume
- 94.91K
- Average Volume
- 148.91K
- Market Capitalization
- $391.88M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $23.33
- Year Low
- $20.71
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
AMEX
Asset Management - Bonds
Financial Services
CDX
N/A
US
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
No key metrics data available.
Company Executives
No executive data available.
Poll Results
No votes yet today — be the first to share your view!
About Simplify High Yield ETF (AMEX:CDX) Stock
The Simplify High Yield ETF (CDX) is engineered to generate substantial current income. It achieves this by primarily allocating its capital to high-yield bonds, while simultaneously deploying strategies to reduce inherent credit risk. CDX offers foundational exposure to the high-yield market, delivering appealing income streams, and is fortified by a diverse array of dynamic and effective credit hedging techniques. Its principal hedging mechanism is rooted in a Quality-Junk factor. Furthermore, the ETF opportunistically invests in CDX call options and equity put options, assessing opportunities based on advantageous cost-to-payout ratios. ...
2026-06-14 05:15:00
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex's leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.
Frequently Asked Questions
-
What is the current Simplify High Yield ETF (CDX) stock price?
-
Simplify High Yield ETF(AMEX:CDX) stock price is $20.805 in the last trading session. During the trading session, CDX stock reached the peak price of $23.33 while $20.71 was the lowest point it dropped to. The percentage change in CDX stock occurred in the recent session was --0.22% while the dollar amount for the price change in CDX stock was -$0.04.
-
CDX's industry and sector of operation?
-
The AMEX listed CDX is part of Asset Management - Bonds industry that operates in the broader Financial Services sector.
-
Who are the executives of CDX?
-
|
|
|
|
| -
How many employees does CDX have?
-
Number of CDX employees currently stands at None. CDX operates from 10845 Griffith Peak Drive, Las Vegas, NV 89135, US.
-
Link for CDX official website?
-
Official Website of CDX is: https://www.simplify.us/etfs/cdx-simplify-high-yield-etf
-
How do I contact CDX?
-
CDX could be contacted at phone #1-855-772-8488 and can also be accessed through its website. CDX operates from 10845 Griffith Peak Drive, Las Vegas, NV 89135, US.
-
How many shares of CDX are traded daily?
-
The average number of CDX shares traded daily for last 3 months was 148.91K.
-
What is the market cap of CDX currently?
-
The market value of CDX currently stands at $391.88M with its latest stock price at $20.805